Beyond Air, Inc. (XAIR): Price and Financial Metrics

Beyond Air, Inc. (XAIR): $2.83

0.14 (-4.71%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

XAIR Price/Volume Stats

Current price $2.83 52-week high $9.28
Prev. close $2.97 52-week low $2.55
Day low $2.82 Volume 227,100
Day high $3.08 Avg. volume 406,692
50-day MA $3.29 Dividend yield N/A
200-day MA $5.31 Market Cap 89.74M

XAIR Stock Price Chart Interactive Chart >


Beyond Air, Inc. (XAIR) Company Bio


Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.


XAIR Latest News Stream


Event/Time News Detail
Loading, please wait...

XAIR Latest Social Stream


Loading social stream, please wait...

View Full XAIR Social Stream

Latest XAIR News From Around the Web

Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release formulation led to reversal of behavioral phenotypes and the nitrosative stress of the Shank3 mouse model of autism. GARDEN CITY, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical co

Yahoo | September 18, 2023

Beyond Air Insiders Placed Bullish Bets Worth US$2.3m

Quite a few insiders have dramatically grown their holdings in Beyond Air, Inc. ( NASDAQ:XAIR ) over the past 12...

Yahoo | September 15, 2023

Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region

Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales GARDEN CITY, New York, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patien

Yahoo | September 7, 2023

Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference

GARDEN CITY, N.Y., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air,

Yahoo | September 6, 2023

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024

GARDEN CITY, N.Y., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debt financing from Avenue Capital Reached agreement with FDA to run a U.S. clinical study in patients hospitalized with viral community acquired pneumonia (VCAP), which will be performed in the 2023-24 winter sea

Yahoo | August 10, 2023

Read More 'XAIR' Stories Here

XAIR Price Returns

1-mo 6.79%
3-mo -38.88%
6-mo -53.91%
1-year -68.42%
3-year -46.40%
5-year -34.49%
YTD -56.39%
2022 -31.25%
2021 79.13%
2020 0.76%
2019 12.47%
2018 -6.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!